<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04399837</url>
  </required_header>
  <id_info>
    <org_study_id>1368-0027</org_study_id>
    <secondary_id>2018-003081-14</secondary_id>
    <nct_id>NCT04399837</nct_id>
  </id_info>
  <brief_title>A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis</brief_title>
  <official_title>Effisayil™ 2: Multi-center, Randomized, Parallel Group, Double Blind, Placebo Controlled, Phase IIb Dose-finding Study to Evaluate Efficacy and Safety of BI 655130 (Spesolimab) Compared to Placebo in Preventing Generalized Pustular Psoriasis (GPP) Flares in Patients With History of GPP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present trial will be performed to characterize the dose-response curve for BI 655130 in
      patients with a history of Generalized Pustular Psoriasis (GPP, per European Rare and Severe
      Psoriasis Expert Network (ERASPEN) criteria) who are now (at screening and at randomization)
      presenting with a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score of
      0 or 1 (clear, or almost clear).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2020</start_date>
  <completion_date type="Anticipated">February 16, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 22, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first Generalized Pustular Psoriasis (GPP) flare</measure>
    <time_frame>up to 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of at least one GPP flare</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first worsening of Psoriasis Symptom Scale (PSS)</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first worsening of Dermatology Quality of Life Index (DLQI)</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained remission</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Defined as a patient with a GPPGA score of 0 or 1 (clear or almost clear) at all visits up to week 48, without intake of rescue medication, or investigator-prescribed Standard of Care (SoC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>up to 64 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Generalized Pustular Psoriasis</condition>
  <arm_group>
    <arm_group_label>Spesolimab, treatment arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Spesolimab, treatment arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Spesolimab, treatment arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spesolimab</intervention_name>
    <description>Solution for injection</description>
    <arm_group_label>Spesolimab, treatment arm 1</arm_group_label>
    <arm_group_label>Spesolimab, treatment arm 2</arm_group_label>
    <arm_group_label>Spesolimab, treatment arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution for injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a known and documented history of GPP per ERASPEN criteria regardless of
             IL36RN mutation status, with at least 2 presentations of moderate to severe GPP flares
             with fresh pustulation (new appearance or worsening) in the past.

          2. Patients with a GPPGA score of 0 or 1 at screening and randomization.

          3. Male or female patients, aged 12 to 75 years at screening. For all patients, a minimum
             weight of 40 kg is required.

          4. Signed and dated written informed consent and assent in accordance with ICH-GCP and
             local legislation prior to admission in the trial.

          5. Women of childbearing potential (WOCBP)1 must be ready and able to use highly
             effective methods of birth control per ICH M3 (R2) that result in a low failure rate
             of less than 1% per year when used consistently and correctly. A list of contraception
             methods meeting these criteria is provided in the Clinical Trial Protocol (CTP) as
             well as in the patient, parent(s) (or patient's legal guardian) information.

        Further inclusion criteria apply.

        Exclusion Criteria:

          1. Patients with SAPHO (Synovitis-acne-pustulosis-hyperostosis-osteitis) syndrome.

          2. Patients with primary erythrodermic psoriasis vulgaris.

          3. Severe, progressive, or uncontrolled hepatic disease, defined as &gt;3-fold Upper Limit
             of Normal (ULN) elevation in Aspartate Aminotransferase (AST) or Alanine
             Aminotransferase (ALT) or alkaline phosphatase, or &gt;2-fold ULN elevation in total
             bilirubin.

          4. Treatment with:

               1. Any restricted medication as specified in the CTP, or any drug considered likely
                  to interfere with the safe conduct of the study, as assessed by the investigator.

               2. Any prior exposure to BI 655130 or another IL36R inhibitor biologic.

          5. Increased risk of infectious complications (e.g. recent pyogenic infection, any
             congenital or acquired immunodeficiency (e.g. HIV), past organ or stem cell
             transplantation), as assessed by the investigator.

          6. Relevant chronic or acute infections including active tuberculosis, human
             immunodeficiency virus (HIV) infection or viral hepatitis at the time of
             randomization. A patient can be re-screened if the patient was treated and is cured
             from the acute infection.

          7. Active or Latent Tuberculosis (TB):

               -  Patients with active tuberculosis should be excluded

               -  Patients with a positive QuantiFERON® (or if applicable, T-Spot®) TB test during
                  screening are excluded, unless the patient had previous diagnosis of active or
                  latent TB and has completed appropriate treatment per the discretion of the local
                  investigator within the last 3 years and at the latest at the time of screening
                  (i.e. 2 to 4 weeks before study drug administration); patients may be re-screened
                  once to meet this criterion)

               -  Patients with suspected false positive or indeterminate QuantiFERON® (or if
                  applicable, T-Spot®) TB result may be re-tested once

               -  If QuantiFERON® (or if applicable, T-Spot®) TB testing is not available or
                  provides indeterminate results after repeat testing, a tuberculin skin test (TST)
                  can be performed: A TST reaction of ≥10mm (≥5mm if receiving ≥15mg/d prednisone
                  or its equivalent) is considered positive.

          8. History of allergy/hypersensitivity to the systemically administered trial medication
             agent or its excipients.

        Further exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Total Skin and Beauty Dermatology Center, PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Krell</last_name>
      <phone>+001 (205) 933-0987</phone>
      <email>jkrellmd@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oakland Hill Dermatology</name>
      <address>
        <city>Auburn Hills</city>
        <state>Michigan</state>
        <zip>48326</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christofer Buatti</last_name>
      <phone>+001 (248) 858-2255</phone>
      <email>chrisbuatti@clinvax.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Kern</last_name>
      <phone>61 3 9342 4531</phone>
      <email>johannes@kerndermatology.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brussels - UNIV Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Dominique Ghislain</last_name>
      <phone>+32 (0)2 764 14 72</phone>
      <email>pierre-dominique.ghislain@uclouvain.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé Bachelez</last_name>
      <phone>+33 (0)1 42 49 98 17</phone>
      <email>herve.bachelez@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Robert Debré</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuelle-Anne Viguier</last_name>
      <phone>+33 (0)3 26 78 43 43</phone>
      <email>mviguier@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Polina Konstantinou</last_name>
      <phone>+33 (0)5 67 77 14 08</phone>
      <email>konstantinou.mp@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Pinter</last_name>
      <phone>+49 (69) 63015418</phone>
      <email>Andreas.Pinter@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg AöR</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolaos Patsinakidis</last_name>
      <phone>+49 (441) 403-0</phone>
      <email>Patsinakidis.Nikolaos@klinikum-oldenburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National Univ. Hosp</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung-Soo Kim</last_name>
      <phone>82 2 2072 4916</phone>
      <email>dockbs@pusan.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seong-Jin Jo</last_name>
      <phone>82 51 240 7338</phone>
      <email>ayin76@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Pulau Pinang</name>
      <address>
        <city>Georgetown Pulau Pinang</city>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wooi Chiang Tan</last_name>
      <phone>6042225250</phone>
      <email>tanwooichiang@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sultanah Aminah</name>
      <address>
        <city>Johor Bahru</city>
        <zip>80100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siew Eng Choon</last_name>
      <phone>+60127162118</phone>
      <email>choonse@yahoo.co.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sultan Ismail</name>
      <address>
        <city>Johor Bahru</city>
        <zip>81100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Latha Selvarajah</last_name>
      <phone>+60164539301</phone>
      <email>lathaselvarajah@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azura Binti Mohd Affandi</last_name>
      <phone>60326155555 (1540)</phone>
      <email>affandi_azura@yahoo.co.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Pakar Sultanah Fatimah</name>
      <address>
        <city>Muar</city>
        <zip>84000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelyn Yap</last_name>
      <phone>+60176823538</phone>
      <email>chervil_82@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hok B. Thio</last_name>
      <phone>+ 31 10 7034580</phone>
      <email>h.thio@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lluis Puig</last_name>
      <phone>+34935565565</phone>
      <email>lpuig@santpau.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Esplugues Del Llobregat</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asuncion Vicente</last_name>
      <phone>+34932532118</phone>
      <email>Avicente@sjdhospitalbarcelona.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Rivera</last_name>
      <phone>+34917792261</phone>
      <email>raquel.rivera@salud.madrid.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 20, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2020</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://trials.boehringer‐ingelheim.com/trial_results/clinical_submission_documents.html to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.
Also, Researchers can use the following link http://trials.boehringer‐ingelheim.com/ to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://trials.boehringer‐ingelheim.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

